Sorrento Therapeutics Inc (NASDAQ: SRNE) recently revealed that it had received the relevant authority from the Food and Drug Administration to proceed with the clinical investigations surrounding its recent drug STI 9167. The company further announced that the regulative body had allowed it to test the productivity of the drug on lively and healthy recruits.
The company plans to recruit patients in the U.S
Sorrento develops the compound as the IV formulation of intranasal 9199 that calms the human body. Following the approvals, the company will begin its recruitment and trials in the U.S. To achieve better and more efficient results, the trials will occur in other areas, including China and Mexico.
The company also intends to continue discussions with the FDA on the adequate termination phase of the study. This intended phase can lead to an Emergency Use Authorization if the clinical trials implement the study’s objectives.
Sorrento develops therapies for autoimmune and malignant diseases
Sorrento is among the revolutionary companies in the biopharmaceutical industry that creates new medicinal therapies for malignant illnesses such as cancer and autoimmune-related illnesses, and others. Since its incorporation, the company has created various ways to treat cancer, thus producing key products, including antibody-drug conjugates and Corvid-19 vaccines.
Its dedication to initiating life-changing therapies is observed through its contributions to treating or reducing the impact of opioid addiction, which is a serious issue in the U.S.
A variety of drugs approved by the FDA includes the SEMDEXA and RTX. Sorrento also possesses a skilled and talented award-winning team responsible for the company’s successes. The company has several renowned subsidiaries with impactful portfolios under its belts, such as ACEA Therapeutics Inc and SmartPharm Therapeutics, among others.
Sorrento Therapeutics is located in San Diego, and its manufacturing plants are located in different areas, including Atlanta and China. Dr Henry Ji, the company’s CEO, stated that the company possesses a distinct portfolio well respected in the biopharmaceutical industry.
Dr Ji further stated that the company developed various assets to treat some malignant illnesses. However, if the assets are combined and other companies collaborate, the effects would be greatly significant.
